SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community debates a strategic upcoming appearance by the CEO on national television, which many investors interpret as a move to build institutional visibility and reinforce the company's precision-oncology platform. While some retail traders are expressing frustration over the lack of immediate clinical catalysts or trial updates, bulls are highlighting recent peer-reviewed AML survival data as strong scientific validation for the company's pipeline and long-term potential.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heavy volatility after reporting strong quarterly revenue growth and raising guidance, though shares have struggled to maintain post-earnings gains amid investor concerns over aggressive capital expenditure plans. The community is actively debating the stock's long-term value, with many traders closely watching the impact of geopolitical tensions and broader market sentiment on the company's turnaround story.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as the community debates a negative CHMP opinion for its drug arimoclomol, while many investors maintain a bullish outlook based on the company's strong cash position, US commercial success, and ongoing appeal process. Despite the stock's significant volatility, discussion is focused on the potential for a long-term recovery, the stability of the core business, and the possibility of a strategic acquisition.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending as investors react to an FDA advisory panel's recommendation to allow the compounding of certain peptides, a development seen as a potential growth catalyst for the company's telehealth platform. While bulls point to this regulatory step as a major opportunity to expand into high-margin wellness markets, community discussion remains polarized due to significant short interest and concerns over the long-term impact of potential regulatory hurdles.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors react to mixed quarterly earnings and the company's decision to slash costs, including significant layoffs and retail store restructuring. The community is actively debating the company's long-term sustainability and dividend security, with sentiment split between bearish concerns over massive debt and bullish confidence in potential cash flow improvements from ongoing AI integration and cost-saving initiatives.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is trending as investors debate the impact of potential satellite partnerships and aggressive share buyback programs against the backdrop of a declining broadband subscriber base. The stock remains a focal point for intense community debate, with bulls citing a low price-to-earnings ratio and massive repurchase potential, while short-sellers point to the company's significant debt load and structural industry challenges.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is drawing significant market attention following a robust fiscal Q1 report that featured a revenue beat and raised EPS guidance, though the stock has experienced volatility as investors weigh the company's guidance against broader macro concerns. Community sentiment remains split between long-term bulls praising the company's strong brand momentum with HOKA and UGG alongside its debt-free balance sheet, and skeptical traders focusing on price action, valuation headwinds, and the impact of analyst downgrades on market sentiment.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares have faced downward pressure following the President's recent proposal to cap credit card interest rates at 10%, raising concerns among investors about potential impacts on credit revenue. While community sentiment reflects anxiety over the regulatory environment and potential margin compression, some market participants remain optimistic, viewing the pullback as a buying opportunity for a resilient, premium-focused brand that remains well-positioned in the financial sector.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors weigh its impressive data center infrastructure growth against a sharp decline in share price following its latest earnings report. While the company delivered a revenue beat and strong guidance driven by optical AI demand, market participants are actively debating whether the pullback represents a buying opportunity or a reaction to heightened volatility and valuation concerns.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as investors react to a strategic $1.5 billion multi-year partnership with Nvidia to expand domestic advanced semiconductor packaging and testing capacity in Arizona. The community is actively debating the stock's long-term potential as a critical AI infrastructure play versus concerns about high capital expenditure requirements and the historically cyclical nature of the OSAT industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well

Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note

Novavax (NVAX) reached $7.88 at the closing of the latest trading day, reflecting a -4.02% change compared to its last close.

HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition

Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.

NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity 

Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day.

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prior day's close.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak 

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Novavax Inc

Investors are tensely anticipating the upcoming earnings call, hoping for concrete updates on CIC data and partnerships to break the recent price stagnation.

Shareholders are voicing intense frustration with CEO John Jacobs, frequently criticizing management's communication, bonus structures, and overall stock performance.

Advocates remain focused on the potential of the proprietary Matrix-M adjuvant technology, suggesting it holds significant long-term value in vaccine development.

Many retail traders are calling for catalysts that could force short sellers out, hoping for a sharp rebound in the share price.

Current Price	$7.83
Prev Close	$7.91
Open	$7.83
Dividend Yield	0.00%
50-Day Moving Average	$9.20
Beta	1.48
Avg. Volume	4.59M
PE Ratio	-13.09

52-Week High	$11.97
52-Week Low	$6.20
Market Capitalization	$1.29B
EPS (Annual)	$2.54
Price to Book	-8.89
Revenue Per Employee	$1.5M

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVAXNovavax Inc

Latest NVAX News